T2EVOLVE’s latest article tackles one of the most important topics in CAR T-cell therapy: lymphodepletion.

While looking into 1271 studies with regard to lymphodepletion stratgies, the authors found that the variability and insufficient amount of detailed information in available and applied drug regimens makes it impossible to design a meta analysis or draw conclusions from these studies.

It highlights the urgent need for rational and standardized approaches which can further be used to model the optimal lymphodepletion strategies for CAR T-cell products.

Share This